Full history for every metric is available with a Kvantra account
Titan Pharmaceuticals, Inc. (TTNP)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 5 | 2 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -2 | -2 | |||||
| Net profit | $m | -21 | -8 | -10 | -6 | -5 | -2 | -2 |
| EPS reported | $ | -2,937 | -431.8 | |||||
| Operating cashflow per share | $ | -4,030 | -3,409 | |||||
| Capex per share | $ | 5.91 | 5.00 | |||||
| FCF per share | $ | -4,035 | -3,414 | |||||
| Free cash flow | $m | -3 | -3 | |||||
| Net debt | $m | -0 | -0 | |||||
| Book value equity | $m | 2 | 2 | |||||
| Book value per share | $ | 1,838 | 1,555 | |||||
| Number of shares | m | 0 | 0 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.00 | 2.00 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.00 | -0.91 | |||||
| EV/EBITDA LTM | x | 0.13 | -1.14 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -63717.0% | -106196.6% | |||||
| FCF Yield | % | -87537.1% | -109.68% | |||||
| Quality | ||||||||
| ROE | % | -159.81% | -121.15% | |||||
| ROIC | % | -155.31% | -155.37% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 0.14 | 0.13 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -8410.1% | -10.54% | |||||
| Net debt/Equity | x | -0.21 | -0.21 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Titan Pharmaceuticals, Inc. is a pharmaceutical company dedicated to creating treatments for chronic conditions, with its product development centered around ProNeura, a unique platform designed for extended drug release. Currently, the company markets the Probuphine implant in Canada and the European Union. This implant provides maintenance treatment for clinically stable individuals struggling with opioid use disorder. Beyond Probuphine, Titan Pharmaceuticals is advancing several pipeline candidates. Among these is the kappa opioid agonist peptide program (TP-2021), which utilizes the ProNeura technology to address chronic pruritus. Another key development is a nalmefene implant program, aimed at preventing opioid relapse in patients after detoxification from opioid use disorder. Furthermore, the company is exploring other applications for its ProNeura platform, including a single implant for HIV prevention and a contraceptive option for women and adolescent girls. Established in 1992, Titan Pharmaceuticals operates from its base in South San Francisco, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Titan Pharmaceuticals, Inc. (TTNP)
Titan Pharmaceuticals, Inc. is a pharmaceutical company dedicated to creating treatments for chronic conditions, with its product development centered around ProNeura, a unique platform designed for extended drug release. Currently, the company markets the Probuphine implant in Canada and the European Union. This implant provides maintenance treatment for clinically stable individuals struggling with opioid use disorder. Beyond Probuphine, Titan Pharmaceuticals is advancing several pipeline candidates. Among these is the kappa opioid agonist peptide program (TP-2021), which utilizes the ProNeura technology to address chronic pruritus. Another key development is a nalmefene implant program, aimed at preventing opioid relapse in patients after detoxification from opioid use disorder. Furthermore, the company is exploring other applications for its ProNeura platform, including a single implant for HIV prevention and a contraceptive option for women and adolescent girls. Established in 1992, Titan Pharmaceuticals operates from its base in South San Francisco, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free